Capricor Advances in DMD Therapy With Positive Study Data - Hims & Hers Health (NYSE:HIMS), Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology firm focused on innovative therapies for rare diseases, has announced favorable three-year results from the ongoing HOPE-2 open-label extension (OLE) study on CAP-1002 for Duchenne muscular dystrophy.

Related Keywords

United States ,Cincinnati ,Ohio , ,Cincinnati Children Hospital Medical Center ,Hims Hers Health ,Cincinnati Children ,Hospital Medical Center ,Biologics License Application ,Market Prospects ,Mordor Intelligence ,Zacks Rank ,Hers Health ,Strong Buy ,Hers Heath ,